NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms


PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and reported financial results for the third quarter of 2024.

Continued here:
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms

Related Posts